Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Consolidated Net Income (2021 - 2025)

Historic Consolidated Net Income for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$13.2 million.

  • ProQR Therapeutics' Consolidated Net Income fell 3781.35% to -$13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$49.2 million, marking a year-over-year decrease of 6988.18%. This contributed to the annual value of -$30.0 million for FY2024, which is 15.84% down from last year.
  • ProQR Therapeutics' Consolidated Net Income amounted to -$13.2 million in Q3 2025, which was down 3781.35% from -$13.9 million recorded in Q2 2025.
  • ProQR Therapeutics' Consolidated Net Income's 5-year high stood at -$3.9 million during Q2 2024, with a 5-year trough of -$20.0 million in Q3 2022.
  • For the 5-year period, ProQR Therapeutics' Consolidated Net Income averaged around -$12.7 million, with its median value being -$12.7 million (2022).
  • As far as peak fluctuations go, ProQR Therapeutics' Consolidated Net Income soared by 5974.5% in 2023, and later tumbled by 25765.03% in 2025.
  • ProQR Therapeutics' Consolidated Net Income (Quarter) stood at -$19.8 million in 2021, then skyrocketed by 35.87% to -$12.7 million in 2022, then surged by 46.95% to -$6.7 million in 2023, then plummeted by 59.73% to -$10.8 million in 2024, then decreased by 22.46% to -$13.2 million in 2025.
  • Its Consolidated Net Income stands at -$13.2 million for Q3 2025, versus -$13.9 million for Q2 2025 and -$11.4 million for Q1 2025.